Login to Your Account



FOB Alternatives

Small Biotechs Find Stakes Too High in Biosimilar Game

By Mari Serebrov
Washington Editor

Tuesday, January 3, 2012

While the U.S. government is betting on biosimilars to cut health care costs, many small biotechs are staying away from the game because of the risks and high stakes. And big biopharma players are upping the ante with multimillion-dollar partnerships with generic drug makers in hopes of a big payout years from now.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription